X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Engineered Treg cell therapy product
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Quellis Biosciences Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 08, 2021
Details:
Under the terms of the agreement, IONTAS / FJB will provide Quell with a diverse panel of novel target binders, ranging in affinities, to enable Quell to select functional binders for chimeric antigen receptor (CAR) development against undisclosed targets.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Undisclosed
Partner/Sponsor/Collaborator: Hemogenyx Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 26, 2020
Details:
GlobalCo will supply the Company with certain biological materials and related confidential information in order for the Company to perform research and development activities to discover and validate novel materials for the treatment of SLE and ther autoimmune diseases.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Antibodies
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Large molecule
Partner/Sponsor/Collaborator: Inotrem
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 07, 2020
Details:
As part of the agreement, IONTAS will apply its Mammalian Display technology to identify antibodies involved in the TREM-1 pathway.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
